Status:
UNKNOWN
TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)
Lead Sponsor:
Fudan University
Conditions:
Colorectal Adenocarcinoma Metastatic to the Liver
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
To date no randomized controlled trials have been completed that demonstrated whether TACE(Transarterial chemoembolization) is an effective adjunct to systemic chemotherapy (target therapy) with respe...
Eligibility Criteria
Inclusion
- Patients must have histologically confirmed CRLM
- disease limited to the liver Unresectable disease by surgery or other local therapies
- Age \> 18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2,child pugh A or B
- Expected survival ≥ 3 months
- Adequate hematological, hepatic and renal function
- PD(progressive disease) after first line chemotherapy
Exclusion
- pregnant or lactating women
- patients with severe organ dysfunction or failure
- with severe cardiovascular or mental disease
Key Trial Info
Start Date :
January 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2021
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT03783559
Start Date
January 1 2016
End Date
March 1 2021
Last Update
June 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of General Surgery, Zhongshan Hospital, Fudan University
Shanghai, China, 200032